Paragon 28, Inc. (FNA)

1 member of Congress has disclosed 2 trades in Paragon 28, Inc. (FNA) via STOCK Act filings. The most recent disclosure was a sale by Gilbert Cisneros on 4 March 2025. Aggregate disclosed activity totals roughly $8K in purchases and $8K in sales (midpoint estimates from bracketed disclosure amounts).

Want to automatically copy Pelosi trades?

Mirror Nancy Pelosi's portfolio with just one click on eToro.

Copy Trading does not amount to investment advice. The value of your investments may go up or down. Your capital is at risk.

Past Performance is not an indication of future results.

Price data is not available for FNA
This ticker may have been delisted, renamed, or is not publicly quoted, so no live price, statistics or chart can be shown. The congressional trades disclosed for it are listed below.

Congressional Trading Activity for FNA

2 transactions
Compliance: 100%
Gilbert Cisneros4 Mar 20257 Apr 2025SaleStock$1,001 - $15,000N/A
Gilbert Cisneros29 Jan 202511 Feb 2025PurchaseStock$1,001 - $15,000N/A

Stock Overview

Market Data

Market Cap

$1.1B

Volume

16.57M

Beta

1.47

P/E Ratio

-19.83

Fundamentals

EPS

$-0.66

Div. Yield

-

Open

$13.09

Day Range

$13.06 – $13.11

Company Information

Sector
Healthcare
Industry
Medical - Devices
Exchange
NYSE · USD
Country
US
CEO
Albert DaCosta
IPO Date
2021-10-15

Paragon 28, Inc. is a medical device company specializing in the development, manufacturing, and global distribution of advanced surgical systems tailored for foot and ankle procedures. Its comprehensive product portfolio encompasses a wide array of...

Earnings

Recent Quarters

Q1 202514 May
EPS$-0.18
Beat 5.3%
Q4 20246 Mar
EPS$-0.13
Miss 8.3%
Q3 202412 Nov
EPS$-0.15
Beat 6.3%
Q2 20248 Aug
EPS$-0.17
Miss 13.3%
Q1 20248 May
EPS$-0.18
Miss 63.6%
Q4 202329 Feb
EPS$-0.19
Miss 90.0%
Q3 20238 Nov
EPS$-0.10
Beat 0.0%
Q2 20232 Aug
EPS$-0.13
Miss 44.4%
Q1 20234 May
EPS$-0.11
Miss 10.0%
Q4 20222 Mar
EPS$-0.51
Miss 466.7%
Q3 202210 Nov
EPS$-0.13
Beat 0.0%
Q2 20223 Aug
EPS$-0.13
Miss 160.0%
Q1 20229 May
EPS$-0.12
Miss 140.0%
Q4 20218 Mar
EPS$-0.07
Beat 22.2%
Q3 202122 Nov
EPS$-0.12
Miss 50.0%
Q2 20219 Sept
EPS$-0.01
Q1 202130 Jun
EPS$-0.03
Q3 202031 Dec
EPS$0.05
Q2 202030 Sept
EPS$0.05
Q1 202030 Jun
EPS$-0.05
Q4 201931 Mar
EPS$-0.05

No dividend data available for this stock.

No stock split data available for this stock.

Similar Stocks

Based on congressional trading patterns

Smart Recommendations
No similar stocks found
No congressional trading patterns available for recommendations

Frequently Asked Questions about FNA

Which members of Congress have traded FNA?
1 member of Congress has disclosed 2 trade in Paragon 28, Inc. (FNA) under the STOCK Act: Gilbert Cisneros.
When was FNA most recently disclosed by Congress?
The most recent FNA disclosure was a sale by Gilbert Cisneros on 4 March 2025.
What is the total disclosed congressional trading volume for FNA?
Members of Congress have disclosed approximately $8K in FNA purchases and $8K in sales. These figures are midpoint estimates derived from the bracketed amount ranges used in STOCK Act filings.
How can I track new congressional trades in FNA?
This FNA page updates as soon as new STOCK Act disclosures are filed for Paragon 28, Inc.. Every trade, politician, transaction date and amount range is surfaced above, typically within hours of the official filing appearing on the House or Senate disclosure portals.
Pelosi Tracker
© 2026 - All rights reserved. Powered by Vantara Labs
Pelosi Tracker is an independent, third-party platform. It is not affiliated with, endorsed by, or in any way associated with Nancy Pelosi, her office or her representatives, or with any other member of Congress. Any use of her name is solely for the purpose of discussing publicly available information.The information provided by Pelosi Tracker is for informational and educational purposes only and is not intended to serve as, nor should it be construed as, financial or investment advice. The data presented here is sourced from publicly available filings and records. While we strive for accuracy, timeliness, and completeness, we do not guarantee that all information is error-free or current.